Aerovate Therapeutics Inc
NASDAQ:JBIO

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:JBIO
Watchlist
Price: 9 USD -8.35% Market Closed
Market Cap: 290.2m USD

Relative Value

There is not enough data to reliably calculate the relative value of JBIO.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

JBIO Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.5
vs History
vs Industry
Median 3Y
-7
Median 5Y
-8.5
Industry
23.6
Forward
-4.2
vs History
vs Industry
Median 3Y
-8.7
Median 5Y
-10.6
Industry
20.2
vs History
vs Industry
Median 3Y
-8.7
Median 5Y
-10.5
Industry
22.9
vs History
70
vs Industry
61
Median 3Y
3.3
Median 5Y
3.1
Industry
2.8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
19
vs Industry
29
Median 3Y
-4.8
Median 5Y
-5.8
Industry
4.9
vs History
19
vs Industry
27
Median 3Y
-4.8
Median 5Y
-5.8
Industry
4.9
Forward
0.1
vs History
19
vs Industry
30
Median 3Y
-6.2
Median 5Y
-6.6
Industry
5.4
vs History
19
vs Industry
26
Median 3Y
-6.2
Median 5Y
-6.6
Industry
4
vs History
vs Industry
2
Median 3Y
144.4
Median 5Y
144.4
Industry
5.1

Multiples Across Competitors

JBIO Competitors Multiples
Aerovate Therapeutics Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Aerovate Therapeutics Inc
NASDAQ:JBIO
75.7m USD 0 -1.1 0 0
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 980 524.7 -161 504.4 -196 117.9 -193 879.9
US
Abbvie Inc
NYSE:ABBV
329.4B USD 5.7 79.3 15.1 22.4
US
Amgen Inc
NASDAQ:AMGN
157.5B USD 4.6 26.5 14.3 23.5
US
Gilead Sciences Inc
NASDAQ:GILD
136.3B USD 4.7 22.9 10 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.6B USD 10.8 -120.9 25.7 27
US
Epizyme Inc
F:EPE
94.1B EUR 2 073.2 -529 -576.1 -560.7
AU
CSL Ltd
ASX:CSL
121.4B AUD 5.2 28.9 17.8 22.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.5B USD 4.2 13.2 11.8 13.3
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.2 -66 -59.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.7B USD 17.3 -151 -676.4 -339
P/S Multiple
Revenue Growth P/S to Growth
US
Aerovate Therapeutics Inc
NASDAQ:JBIO
Average P/S: 3 398 267.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 980 524.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.8
10%
1.1
US
E
Epizyme Inc
F:EPE
2 073.2
N/A N/A
AU
CSL Ltd
ASX:CSL
5.2
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
20
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.3
30%
0.6
P/E Multiple
Earnings Growth PEG
US
Aerovate Therapeutics Inc
NASDAQ:JBIO
Average P/E: 34.2
Negative Multiple: -1.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 504.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
79.3
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.5
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.9
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -120.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529 N/A N/A
AU
CSL Ltd
ASX:CSL
28.9
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -151 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Aerovate Therapeutics Inc
NASDAQ:JBIO
Average EV/EBITDA: 13.5
0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 117.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.3
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.1 N/A N/A
AU
CSL Ltd
ASX:CSL
17.8
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -676.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Aerovate Therapeutics Inc
NASDAQ:JBIO
Average EV/EBIT: 17.4
0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 879.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.4
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.5
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.7 N/A N/A
AU
CSL Ltd
ASX:CSL
22.2
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -339 N/A N/A